Company: MYGN
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0000899923-25-000010
Chunk: 1

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-24
Form: 8-K
Item: Item 2.02
Chunk 1
---
 Genomics Group, of Agilent Technologies, Inc. (“ Agilent”) from April 2018 to December 2023. From May 2017 to April 2018, Mr. Raha served as Agilent's Senior Vice President, Strategy and Corporate Development. From July 2013 to January 2017, he served as Vice President, Global Marketing for Illumina, Inc., and from 2008 to 2012, he served as Vice President and General Manager, Genomics Assays / NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University.

In connection with his new appointment, on February 24, 2025, the Company entered into an amended and restated employment agreement with Mr. Raha (the “ Raha Employment Agreement”) setting forth Mr. Raha’s compensation and certain other terms with respect to his employment as President and Chief Executive Officer of the Company. Pursuant to the Raha Employment Agreement, Mr. Raha will become President and Chief Executive Officer of the Company as of the Effective Date, at which time he will be paid an annual base salary of $920,000. Mr. Raha will be eligible to receive an annual target cash bonus equal to 100% of his annual base salary upon achievement of goals to be established by the Compensation and Human Capital Committee of the Board (the “ CHCC”) each fiscal year and will be eligible to participate in the Company’s annual long-term incentive compensation program. Mr. Raha will also be eligible to participate in the standard health, welfare and retirement benefit plans that are applicable to similarly situated executives of the Company. The Raha Employment Agreement also provides for a one-time grant of 141,050 restricted stock units (“ RSUs”) (the “ Raha RSU Promotion Grant”) to Mr. Raha in connection with his promotion. The Raha RSU Promotion Grant will be subject to performance-based vesting in four equal installments based upon the achievement of certain stock price targets, provided that no portion of the Raha RSU Promotion Grant shall vest earlier than the first anniversary of the Effective Date. The Raha Employment Agreement also provides that Mr. Raha will be entitled to a grant in 2025 of an additional equity award of RSUs valued at up to $6,000,000 in accordance with the Company’s annual equity grant cycle, with such award consisting of (i